Menlo Park, United States
AN2 Therapeutics, founded in 2019, is a promising biopharmaceutical startup headquartered in the United States. The company is spearheading efforts in the biotechnology and healthcare sectors with its noteworthy focus on developing therapies for rare, chronic, and serious infectious diseases.
The company's core innovation lies in its advanced boron chemistry platform, which is used to create novel small molecule therapeutics. AN2 Therapeutics is actively developing a pipeline of boron-based compounds targeting diseases such as Chagas disease, melioidosis, and NTM lung disease caused by M. abscessus. Additionally, the company has initiatives aimed at combating oncology and other infectious diseases, addressing critical unmet medical needs.
Recently, AN2 Therapeutics received a grant investment from the distinguished Bill & Melinda Gates Foundation on 26 September 2023, highlighting investor confidence in its potential impact on global health. This backing not only underscores the strategic importance of their research but also positions the company well for future growth and partnerships.
